Company / Capital Expenditures
Vistagen Therapeutics, Inc. Capital Expenditures History
FY2017-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
-
FY2023
5-year range
$0 / $275.4K
FY2019-FY2023
Trend
-100.0%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Remained stable around $0 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2023, capital expenditures decreased 100.0% year-over-year.
- Peak capital expenditures was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -7.17 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | $0 | -100.0% |
| FY2022 | $275.4K | - |
| FY2021 | $0 | -100.0% |
| FY2018 | $239.1K | +809.1% |
| FY2017 | $26.3K | - |
| FY2014 | - | - |
| FY2012 | - | - |
| FY2011 | - | - |
As of FY2023 · SEC 10-K · Updated Jun 28, 2026